{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:11:42Z","timestamp":1742443902455,"version":"3.40.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,19]]},"DOI":"10.7759\/cureus.80808","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:07:01Z","timestamp":1742375221000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapidly Progressing Prostate Cancer With Low Prostate-Specific Antigen and Gleason Score 5+5: A Case Report"],"prefix":"10.7759","author":[{"given":"Kosuke","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuaki","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson IM","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ, et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004, 350:2239-46. 10.1056\/NEJMoa031918","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.09.014","article-title":"Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen","volume":"34","author":"Falchook AD","year":"2016","unstructured":"Falchook AD, Martin NE, Basak R, Smith AB, Milowsky MI, Chen RC. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen. Urol Oncol. 2016, 34:119.e19-26. 10.1016\/j.urolonc.2015.09.014","journal-title":"Urol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.002","article-title":"Prognosis of Gleason Score 9-10 prostatic adenocarcinoma in needle biopsies: A nationwide population-based study","volume":"7","author":"Egevad L","year":"2024","unstructured":"Egevad L, Micoli C, Samaratunga H, Delahunt B, Garmo H, Stattin P, Eklund M. Prognosis of Gleason Score 9-10 prostatic adenocarcinoma in needle biopsies: A nationwide population-based study. Eur Urol Oncol. 2024, 7:213-21. 10.1016\/j.euo.2023.11.002","journal-title":"Eur Urol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2020.02.024","article-title":"Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study","volume":"76","author":"Song P","year":"2020","unstructured":"Song P, Yang B, Peng Z, et al.. Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study. Int J Surg. 2020, 76:64-8. 10.1016\/j.ijsu.2020.02.024","journal-title":"Int J Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29691","article-title":"Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer","volume":"122","author":"Mahal BA","year":"2016","unstructured":"Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016, 122:78-83. 10.1002\/cncr.29691","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.017","article-title":"A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer","volume":"181","author":"Fankhauser CD","year":"2023","unstructured":"Fankhauser CD, Parry MG, Ali A, et al.. A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer. Eur J Cancer. 2023, 181:70-8. 10.1016\/j.ejca.2022.12.017","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2022.07.002","article-title":"De novo neuroendocrine features in prostate cancer","volume":"127","author":"Abdulfatah E","year":"2022","unstructured":"Abdulfatah E, Fine SW, Lotan TL, Mehra R. De novo neuroendocrine features in prostate cancer. Hum Pathol. 2022, 127:112-22. 10.1016\/j.humpath.2022.07.002","journal-title":"Hum Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33503","article-title":"Prostate-specific antigen levels of \u22644 and >4 ng\/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer","volume":"127","author":"Kim DW","year":"2021","unstructured":"Kim DW, Chen MH, Wu J, Huland H, Graefen M, Tilki D, D'Amico AV. Prostate-specific antigen levels of \u22644 and >4 ng\/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. Cancer. 2021, 127:2222-8. 10.1002\/cncr.33503","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2016.2.150","article-title":"Malignant priapism due to penile metastases: Case series and literature review","volume":"88","author":"De Luca F","year":"2016","unstructured":"De Luca F, Zacharakis E, Shabbir M, et al.. Malignant priapism due to penile metastases: Case series and literature review. Arch Ital Urol Androl. 2016, 88:150-2. 10.4081\/aiua.2016.2.150","journal-title":"Arch Ital Urol Androl"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal BA","year":"2018","unstructured":"Mahal BA, Yang DD, Wang NQ, et al.. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol. 2018, 74:146-54. 10.1016\/j.eururo.2018.01.043","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-020-01005-x","article-title":"Role of mpMRI in benign prostatic hyperplasia assessment and treatment","volume":"21","author":"Walker SM","year":"2020","unstructured":"Walker SM, Turkbey B. Role of mpMRI in benign prostatic hyperplasia assessment and treatment. Curr Urol Rep. 2020, 21:55. 10.1007\/s11934-020-01005-x","journal-title":"Curr Urol Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7150\/jca.40428","article-title":"Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: A population-matched study","volume":"11","author":"Kang Y","year":"2020","unstructured":"Kang Y, Song P, Fang K, et al.. Survival outcomes of low prostate-specific antigen levels and T stages in patients with high-grade prostate cancer: A population-matched study. J Cancer. 2020, 11:6484-90. 10.7150\/jca.40428","journal-title":"J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1587","article-title":"Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer","volume":"25","author":"Spratt DE","year":"2019","unstructured":"Spratt DE, Alshalalfa M, Fishbane N, et al.. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment na\u00efve primary prostate cancer. Clin Cancer Res. 2019, 25:6721-30. 10.1158\/1078-0432.CCR-19-1587","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson D","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, et al.. Integrative clinical genomics of advanced prostate cancer. Cell. 2015, 162:454. 10.1016\/j.cell.2015.06.053","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu P","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, et al.. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017, 355:84-8. 10.1126\/science.aah4307","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver BS","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, et al.. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011, 19:575-86. 10.1016\/j.ccr.2011.04.008","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.08.033","article-title":"Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer","volume":"75","author":"Yang DD","year":"2019","unstructured":"Yang DD, Mahal BA, Muralidhar V, et al.. Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer. Eur Urol. 2019, 75:35-41. 10.1016\/j.eururo.2018.08.033","journal-title":"Eur Urol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40787","article-title":"Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA levels: A meta-analysis","volume":"6","author":"Mahal BA","year":"2023","unstructured":"Mahal BA, Kwak L, Xie W, et al.. Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA levels: A meta-analysis. JAMA Netw Open. 2023, 6:e2340787. 10.1001\/jamanetworkopen.2023.40787","journal-title":"JAMA Netw Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13052","article-title":"Prostate penile metastasis: Incidence and imaging pattern on (68) Ga-PSMA PET\/CT","volume":"64","author":"Tatkovic A","year":"2020","unstructured":"Tatkovic A, McBean R, Schoeman J, Wong D. Prostate penile metastasis: Incidence and imaging pattern on (68) Ga-PSMA PET\/CT. J Med Imaging Radiat Oncol. 2020, 64:499-504. 10.1111\/1754-9485.13052","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339780-rapidly-progressing-prostate-cancer-with-low-prostate-specific-antigen-and-gleason-score-55-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:07:03Z","timestamp":1742375223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339780-rapidly-progressing-prostate-cancer-with-low-prostate-specific-antigen-and-gleason-score-55-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.80808","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}